Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 418 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neonatal Respiratory Distress Syndrome Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742
View directory record Official record
Conditions
PPROM, Respiratory Distress Syndrome in Premature Infants
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Breathing Patterns in Infants Before and After Extubation

NCT07542301
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS), PreTerm Neonate
Interventions
Observation
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
0 Days to 6 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
No Longer Available No phase listed Expanded access

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

NCT03582930
View directory record Official record
Conditions
Neonatal Respiratory Distress
Interventions
Infasurf Aero
Combination Product
Lead sponsor
ONY
Industry
Eligibility
Up to 42 Weeks
U.S. locations
5
States / cities
Jackson, Mississippi • Buffalo, New York • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 3:18 PM EDT
Terminated Phase 3 Interventional Results available

Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)

NCT00796419
View directory record Official record
Conditions
Lung Injury, Acute (ALI), Respiratory Distress Syndrome, Acute (ARDS)
Interventions
5% human albumin, 6% hetastarch
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 21, 2026, 3:18 PM EDT
Terminated Phase 1 Interventional Results available

Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)

NCT05027815
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Interventions
Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 21, 2026, 3:18 PM EDT
No Longer Available No phase listed Expanded access

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830
View directory record Official record
Conditions
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Interventions
Remestemcel-L
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting No phase listed Observational

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

NCT06690801
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years to 21 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Aerosol Box Use on Healthcare Provider Contamination

NCT04880668
View directory record Official record
Conditions
Coronavirus, Covid19, COVID-19 Acute Respiratory Distress Syndrome
Interventions
Aerosol Box (Splashguard)
Device
Lead sponsor
KidSIM Simulation Program
Network
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 21, 2026, 3:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Completed No phase listed Observational

An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

NCT06272942
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS)
Interventions
An ICU admission and a temporally related ARDS diagnosis
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
640,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting Not applicable Interventional

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

NCT07442669
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
27 Weeks to 34 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Betamethasone Dosing Interval - 12 or 24 Hours?

NCT00453141
View directory record Official record
Conditions
Preterm Delivery
Interventions
dosing of Betamethasone
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Camden, New Jersey • Pomona, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 10, 2009 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting No phase listed Observational

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

NCT07125079
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Results available

Early Insulin and Development of ARDS

NCT00605696
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alveolar Macrophage Programming Following Endotoxin Exposure

NCT03859050
View directory record Official record
Conditions
ARDS, Human
Interventions
bronchoscopy with intrabronchial administration of lipopolysaccharide
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2032
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Not applicable Interventional

Fluid Restriction in Respiratory Distress of the Newborn

NCT03120585
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Fluid Management Intervention
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 12 Hours
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • Lawton, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 21, 2026, 3:18 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Recruiting Phase 2 Interventional

Clazakizumab vs. Placebo - COVID-19 Infection

NCT04494724
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Not applicable Interventional

The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study

NCT00739115
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Heliox gas
Other
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Minute to 12 Hours
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Phase 3 Interventional

Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)

NCT00883948
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
39
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 21, 2026, 3:18 PM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 21, 2026, 3:18 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 21, 2026, 3:18 PM EDT